

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled phase 2 trial

Lancet, The

392, 2180-2193

DOI: [10.1016/s0140-6736\(18\)32260-8](https://doi.org/10.1016/s0140-6736(18)32260-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	European Association for the Study of Diabetes 2018. Journal of Diabetes, 2018, 11, 179-182.	0.8	0
2	Twice the benefits with twincretins?. Lancet, The, 2018, 392, 2142-2144.	6.3	5
3	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 2018, 18, 3-14.	3.0	400
4	“Let’s Stay Together”, GIP and GLP-1 dual agonism in the treatment of metabolic disease. Molecular Metabolism, 2018, 18, 1-2.	3.0	8
5	Testing a novel dual receptor agonist for treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2018, 14, 687-687.	4.3	2
6	Ten-year Medicare budget impact of increased coverage for anti-obesity intervention. Journal of Medical Economics, 2019, 22, 1096-1104.	1.0	9
7	The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice. Diabetologia, 2019, 62, 1928-1937.	2.9	14
8	Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. Expert Opinion on Drug Discovery, 2019, 14, 1151-1159.	2.5	9
10	Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. Cell Metabolism, 2019, 30, 987-996.e6.	7.2	171
11	The future of new drugs for diabetes management. Diabetes Research and Clinical Practice, 2019, 155, 107785.	1.1	28
12	A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor. International Journal of Molecular Sciences, 2019, 20, 3532.	1.8	19
14	Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs, 2019, 79, 1187-1197.	4.9	15
15	A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture. Hormones, 2019, 18, 401-408.	0.9	2
16	NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. Trends in Endocrinology and Metabolism, 2019, 30, 891-902.	3.1	80
17	Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice. European Journal of Pharmacology, 2019, 865, 172733.	1.7	1
18	Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice. Clinical Medicine Insights: Endocrinology and Diabetes, 2019, 12, 117955141987545.	1.0	15
19	Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Therapy, 2019, 10, 2183-2199.	1.2	28
20	Physiology of the Incretin Hormones, GIP and GLP-1 “Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38

#	ARTICLE	IF	CITATIONS
21	Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 153997.	1.5	62
22	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4092.	1.8	47
23	Physiological roles of the GIP receptor in murine brown adipose tissue. <i>Molecular Metabolism</i> , 2019, 28, 14-25.	3.0	36
24	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. <i>Metabolism: Clinical and Experimental</i> , 2019, 100, 153960.	1.5	16
25	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	3.0	850
26	&lt;p&gt;Dual GIP&quot;GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1973-1985.	1.1	46
27	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , 2019, 62, 665-675.	2.9	81
28	Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. <i>Drugs</i> , 2019, 79, 219-230.	4.9	170
29	Metabolic Targets in Nonalcoholic Fatty Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 247-267.	2.3	91
30	GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. <i>Diabetes</i> , 2019, 68, 897-900.	0.3	39
31	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 377-387.	0.6	8
32	Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?. <i>Frontiers in Physiology</i> , 2019, 10, 457.	1.3	33
33	Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 421-431.	2.5	11
34	Metabolic surgery for the treatment of type 2 diabetes in patients with BMI lower than 35&Akg/m <sup>2</sup> : Why caution is still needed. <i>Obesity Reviews</i> , 2019, 20, 633-647.	3.1	11
35	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2953-2960.	1.8	41
37	Weight loss variability with SGLT2 inhibitors and GLP&quot;1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. <i>Obesity Reviews</i> , 2019, 20, 816-828.	3.1	139
38	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881983486.	1.4	76
39	Beyond glycemic control: New guidance on cardio-renal protection. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 113-115.	1.5	5

#	ARTICLE	IF	CITATIONS
40	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 66-91.	2.5	28
41	Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1168-1176.	2.2	1
42	Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. <i>Nature Reviews Endocrinology</i> , 2019, 15, 226-237.	4.3	350
43	Current Treatments on Obesity. <i>Korean Journal of Health Promotion</i> , 2019, 19, 171.	0.1	2
44	Gut Peptide Agonism in the Treatment of Obesity and Diabetes. , 2019, 10, 99-124.		4
45	Cardioprotective diabetes drugs: what cardiologists need to know. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 96-105.	0.5	11
46	News and Views: A Roundup of some new developments in diabetes. <i>Diabetic Medicine</i> , 2019, 36, 129-132.	1.2	1
47	Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. <i>Molecular Metabolism</i> , 2019, 20, 51-62.	3.0	130
48	Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. <i>Nature Reviews Endocrinology</i> , 2019, 15, 90-104.	4.3	92
49	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12664.	1.2	29
50	Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. <i>Journal of Diabetes Investigation</i> , 2019, 10, 902-905.	1.1	18
51	The Regulation of Peripheral Metabolism by Gut-Derived Hormones. <i>Frontiers in Endocrinology</i> , 2018, 9, 754.	1.5	42
52	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 905-927.	2.9	34
53	Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. <i>Neuropharmacology</i> , 2020, 162, 107813.	2.0	37
54	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 104-126.	1.8	57
55	Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 122-132.	1.2	27
56	New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling. <i>Journal of Molecular Biology</i> , 2020, 432, 1347-1366.	2.0	40
57	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. <i>Peptides</i> , 2020, 125, 170176.	1.2	3

#	ARTICLE	IF	CITATIONS
58	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	1.2	61
59	The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. <i>Peptides</i> , 2020, 125, 170194.	1.2	21
60	Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?. <i>Endocrine Reviews</i> , 2020, 41, 1-21.	8.9	55
61	GIP's involvement in the pathophysiology of type 2 diabetes. <i>Peptides</i> , 2020, 125, 170178.	1.2	18
62	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e502-e510.	1.8	12
63	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. <i>Peptides</i> , 2020, 125, 170174.	1.2	27
64	Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes. <i>Molecular and Cellular Endocrinology</i> , 2020, 503, 110696.	1.6	34
65	Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor. <i>MABs</i> , 2020, 12, 1710047.	2.6	7
66	Pharmacological antagonism of the incretin system protects against diet-induced obesity. <i>Molecular Metabolism</i> , 2020, 32, 44-55.	3.0	37
67	Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review. <i>Peptides</i> , 2020, 125, 170224.	1.2	27
68	Metabolic Benefits of MicroRNA-22 Inhibition. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 104-116.	2.0	17
69	The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119. <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 112017.	2.6	21
70	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. <i>Acta Diabetologica</i> , 2020, 57, 583-587.	1.2	5
71	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154031.	1.5	12
72	Cardiovascular biology of the GIP receptor. <i>Peptides</i> , 2020, 125, 170228.	1.2	10
73	Incretin therapy for diabetes mellitus type 2. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 2-10.	1.2	21
74	A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice. <i>Biochemical Pharmacology</i> , 2020, 171, 113723.	2.0	9
75	Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, 146-157.	0.3	11

#	ARTICLE	IF	CITATIONS
76	Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. <i>Peptides</i> , 2020, 125, 170201.	1.2	15
77	The role of GIP in $\hat{\pm}$ -cells and glucagon secretion. <i>Peptides</i> , 2020, 125, 170213.	1.2	49
78	Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. <i>Peptides</i> , 2020, 125, 170225.	1.2	30
79	GIP analogues and the treatment of obesity-diabetes. <i>Peptides</i> , 2020, 125, 170202.	1.2	34
80	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Peptides</i> , 2020, 125, 170208.	1.2	39
81	Obesity medications in development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 63-71.	1.9	30
82	Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. <i>Neuroscience</i> , 2020, 447, 191-215.	1.1	11
83	Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. <i>Nature Communications</i> , 2020, 11, 4981.	5.8	57
84	The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2451-2459.	2.2	83
85	Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 379-394.	1.2	37
86	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , 2020, 18, 322.	2.3	5
87	Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 43-60.	0.7	47
88	The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020, 35, 153331752095304.	0.9	29
89	Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. <i>Science Advances</i> , 2020, 6, eaaz9890.	4.7	40
90	Hope in Hopeless Times: Gearing Up to Fight the Obesity Pandemic. <i>Endocrinology</i> , 2020, 161, .	1.4	2
91	The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor. <i>Frontiers in Pharmacology</i> , 2020, 11, 1271.	1.6	5
92	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5820.	1.8	38
93	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. <i>Pharmaceutics</i> , 2020, 12, 790.	2.0	23

#	ARTICLE	IF	CITATIONS
94	Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches. <i>Biology</i> , 2020, 9, 473.	1.3	35
95	Recent Updates on Obesity Treatments: Available Drugs and Future Directions. <i>Neuroscience</i> , 2020, 437, 215-239.	1.1	46
96	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , 2020, 20, 26.	1.7	17
97	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. <i>Gut</i> , 2020, 69, 1877-1884.	6.1	127
98	The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. <i>Current Obesity Reports</i> , 2020, 9, 136-149.	3.5	18
99	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 34-53.	6.6	21
100	The gut hormone receptor GIPR links energy availability to the control of hematopoiesis. <i>Molecular Metabolism</i> , 2020, 39, 101008.	3.0	12
101	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 595-602.	1.9	34
102	GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2710-e2716.	1.8	97
103	A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 353-362.	1.3	5
104	The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (<sc>GLP</sc>-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <sc>long-acting GLP</sc>-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1886-1891.	2.2	53
105	A Role for GLP-1 in Treating Hyperphagia and Obesity. <i>Endocrinology</i> , 2020, 161, .	1.4	52
106	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1565-1577.	0.9	13
107	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1907.	1.8	42
108	Glucagon-based therapy: Past, present and future. <i>Peptides</i> , 2020, 127, 170296.	1.2	22
109	Advances in therapeutic peptides targeting G protein-coupled receptors. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 389-413.	21.5	162
110	Leveraging the Gut to Treat Metabolic Disease. <i>Cell Metabolism</i> , 2020, 31, 679-698.	7.2	53
111	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1328-1338.	2.2	26

#	ARTICLE	IF	CITATIONS
112	How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends in Endocrinology and Metabolism, 2020, 31, 410-421.	3.1	170
113	New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. Bioconjugate Chemistry, 2020, 31, 1167-1176.	1.8	21
114	Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function. , 2020, 10, 577-595.		16
115	Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions. Clinical Medicine Insights: Endocrinology and Diabetes, 2020, 13, 117955142090584.	1.0	17
116	Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus. Endocrinology, 2020, 161, .	1.4	20
117	Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity. Cells, 2020, 9, 1596.	1.8	19
118	The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. Current Obesity Reports, 2020, 9, 255-271.	3.5	39
119	Labeling and Characterization of Human GLP-1-Secreting L-cells in Primary Ileal Organoid Culture. Cell Reports, 2020, 31, 107833.	2.9	42
120	What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery, 2020, 15, 1253-1265.	2.5	6
121	Modern pharmacological treatment of obese patients. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201881989752.	1.4	55
122	Exploring G Protein-Coupled Receptor Signaling in Primary Pancreatic Islets. Biological Procedures Online, 2020, 22, 4.	1.4	7
123	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease – A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 1509.	1.8	29
124	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in Experimental Medicine and Biology, 2020, 1307, 171-192.	0.8	64
125	Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides, 2020, 125, 170233.	1.2	26
126	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	4.3	38
127	Reflections on Diabetes Care at the End of the Second Decade of the 21st Century. Diabetes Technology and Therapeutics, 2020, 22, 63-65.	2.4	2
128	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, Obesity and Metabolism, 2020, 22, 938-946.	2.2	126
129	The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 523-542.	1.5	43



#	ARTICLE	IF	CITATIONS
130	Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials. <i>Endocrine</i> , 2020, 68, 508-517.	1.1	6
131	Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. <i>Biochemical Pharmacology</i> , 2020, 177, 114001.	2.0	37
132	Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. <i>Journal of Controlled Release</i> , 2020, 322, 486-508.	4.8	106
133	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 953-967.	0.9	28
134	Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1352-1355.	4.3	186
135	Endoscopic intragastric balloon: a gimmick or a viable option for obesity?. <i>Annals of Translational Medicine</i> , 2020, 8, S8-S8.	0.7	17
136	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. <i>Diabetes Therapy</i> , 2020, 11, 1199-1216.	1.2	123
137	An "Ayurveda-Biology"™ platform for integrative diabetes management. <i>Journal of Ethnopharmacology</i> , 2021, 268, 113575.	2.0	15
138	Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 195-207.	2.2	12
139	GLP-1 receptor agonists in the treatment of type 2 diabetes " state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	3.0	518
140	Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 28-34.	0.7	1
141	Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. <i>Bioorganic Chemistry</i> , 2021, 106, 104492.	2.0	11
142	Genetic and biased agonist-mediated reductions in $\beta^2$ -arrestin recruitment prolong cAMP signaling at glucagon family receptors. <i>Journal of Biological Chemistry</i> , 2021, 296, 100133.	1.6	41
143	The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin. <i>Biochemical Pharmacology</i> , 2021, 183, 114355.	2.0	6
144	Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy. <i>Molecular Metabolism</i> , 2021, 43, 101118.	3.0	8
145	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 388-396.	1.8	129
146	Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. <i>Molecular Metabolism</i> , 2021, 46, 101139.	3.0	58
147	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. <i>Diabetes Therapy</i> , 2021, 12, 143-157.	1.2	154

#	ARTICLE	IF	CITATIONS
148	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. <i>Molecular Metabolism</i> , 2021, 46, 101153.	3.0	10
149	Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 50-62.	2.2	53
150	Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. <i>Nutrients</i> , 2021, 13, 351.	1.7	28
151	Metabolic Messengers: glucagon-like peptide 1. <i>Nature Metabolism</i> , 2021, 3, 142-148.	5.1	73
152	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 612722.	1.3	11
153	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110343.	1.4	7
154	Mechanisms controlling pancreatic islet cell function in insulin secretion. <i>Nature Reviews Molecular Cell Biology</i> , 2021, 22, 142-158.	16.1	277
155	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 660.	1.8	15
156	Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110421.	1.4	12
158	Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes. , 2021, , .		1
160	Association of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity. <i>Nutrients</i> , 2021, 13, 613.	1.7	16
161	Therapeutic pipeline in nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 373-392.	8.2	173
162	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 17-35.	2.2	27
163	Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography. <i>Diabetes</i> , 2021, 70, 842-853.	0.3	10
164	An update on pharmacotherapeutic strategies for obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1305-1318.	0.9	6
166	The Role of Incretins on Insulin Function and Glucose Homeostasis. <i>Endocrinology</i> , 2021, 162, .	1.4	43
167	In Vitro and In Vivo Effects of <i>Palmaria palmata</i> Derived Peptides on Glucose Metabolism. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 1667-1676.	0.9	3
168	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. <i>Drugs and Aging</i> , 2021, 38, 355-373.	1.3	8

#	ARTICLE	IF	CITATIONS
169	Safety and efficacy of an extended-release peptide <sc>YY</sc> analogue for obesity: A randomized, placebo-controlled, phase <sc>1</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1471-1483.	2.2	9
170	Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2805.	1.8	8
171	Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion. <i>Nutrients</i> , 2021, 13, 883.	1.7	39
172	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1049-1059.	1.6	27
173	Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism. <i>PLoS ONE</i> , 2021, 16, e0249239.	1.1	13
174	The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. <i>Molecular Metabolism</i> , 2021, 46, 101175.	3.0	29
175	GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E835-E845.	1.8	17
176	Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells. <i>FASEB Journal</i> , 2021, 35, e21534.	0.2	6
177	Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. <i>Molecular Metabolism</i> , 2021, 46, 101090.	3.0	150
178	Promising areas of pharmacotherapy for obesity. <i>Russian Journal of Cardiology</i> , 2021, 26, 4279.	0.4	3
180	The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. <i>Cell Metabolism</i> , 2021, 33, 833-844.e5.	7.2	128
181	Liver-targeting drugs and their effect on blood glucose and hepatic lipids. <i>Diabetologia</i> , 2021, 64, 1461-1479.	2.9	21
182	The Human Islet: Mini-Organ With Mega-Impact. <i>Endocrine Reviews</i> , 2021, 42, 605-657.	8.9	44
183	Future directions in obesity pharmacotherapy. <i>European Journal of Internal Medicine</i> , 2021, 93, 13-20.	1.0	16
184	The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. <i>Frontiers in Endocrinology</i> , 2021, 12, 678055.	1.5	32
185	Old Paradoxes and New Opportunities for Appetite Control in Obesity. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 264-294.	3.1	22
186	GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. <i>Cell Reports Medicine</i> , 2021, 2, 100263.	3.3	30
187	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70

#	ARTICLE	IF	CITATIONS
188	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. <i>British Journal of Pharmacology</i> , 2022, 179, 695-714.	2.7	55
189	The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective. <i>Diabetes Therapy</i> , 2021, 12, 1821-1837.	1.2	7
190	What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?. <i>Cell Reports Medicine</i> , 2021, 2, 100284.	3.3	4
191	The therapeutic potential of GLP-1 receptor biased agonism. <i>British Journal of Pharmacology</i> , 2022, 179, 492-510.	2.7	27
192	The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 599-612.	8.2	346
193	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , 2021, 38, e14592.	1.2	1
194	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2233.	1.0	15
195	Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing. <i>Organic Process Research and Development</i> , 2021, 25, 1628-1636.	1.3	26
196	GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	78
197	New drugs for NASH. <i>Liver International</i> , 2021, 41, 112-118.	1.9	34
198	New Aspects of Diabetes Research and Therapeutic Development. <i>Pharmacological Reviews</i> , 2021, 73, 1001-1015.	7.1	10
199	GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. <i>Diabetes</i> , 2021, 70, 1938-1944.	0.3	17
200	The specification and function of enteroendocrine cells in <i>Drosophila</i> and mammals: a comparative review. <i>FEBS Journal</i> , 2022, 289, 4773-4796.	2.2	29
201	Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed mice. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2215-2225.	2.2	4
202	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 503-515.	13.9	668
203	Peptidomics of enteroendocrine cells and characterisation of potential effects of a novel preprogastrin derived-peptide on glucose tolerance in lean mice. <i>Peptides</i> , 2021, 140, 170532.	1.2	7
204	The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. <i>Diabetes</i> , 2021, 70, 1929-1937.	0.3	22
205	The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. <i>Diabetes</i> , 2021, 70, 1956-1961.	0.3	22

#	ARTICLE	IF	CITATIONS
206	TCF7 is not essential for glucose homeostasis in mice. <i>Molecular Metabolism</i> , 2021, 48, 101213.	3.0	1
207	Clinical management and treatment of obesity in China. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 393-405.	5.5	105
208	Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex. <i>Diabetes</i> , 2021, 70, 1945-1955.	0.3	13
209	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 813-825.	1.9	16
210	Alliances of the gut and bone axis. <i>Seminars in Cell and Developmental Biology</i> , 2022, 123, 74-81.	2.3	16
211	Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 143-155.	6.3	407
212	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-22.	0.9	2
213	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. <i>Journal of Women's Health</i> , 2021, 30, 1016-1027.	1.5	5
214	Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). <i>Diabetes Therapy</i> , 2021, 12, 2133-2147.	1.2	20
215	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 231-243.	1.0	51
216	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 33-45.	1.9	21
217	Pharmacotherapy of obesity: An update. <i>Pharmacological Research</i> , 2021, 169, 105649.	3.1	28
218	A unified approach for evaluating the prediction of treatment effect across different types of endpoints. <i>Pharmaceutical Statistics</i> , 2021, , .	0.7	0
219	Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	8
221	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1193-1204.	1.3	12
222	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. <i>Biochemical Pharmacology</i> , 2021, 190, 114656.	2.0	8
223	Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 44, 116291.	1.4	4
224	Obesity as a Risk Factor for Severe COVID-19: Summary of the Best Evidence and Implications for Health Care. <i>Current Obesity Reports</i> , 2021, 10, 282-289.	3.5	41

#	ARTICLE	IF	CITATIONS
225	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.	5.5	121
226	Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1453-1460.	2.8	4
227	Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the <i>GIPR</i> Region. <i>Diabetes</i> , 2021, 70, 2706-2719.	0.3	12
228	GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models. <i>Diabetes</i> , 2021, 70, 2545-2553.	0.3	59
229	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. <i>Lancet</i> , 2021, 398, 583-598.	6.3	274
230	Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding. <i>Journal of Physiology</i> , 2022, 600, 1053-1078.	1.3	15
231	A primer on obesity-related cardiomyopathy. <i>Physiological Reviews</i> , 2022, 102, 1-6.	13.1	9
232	A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs. <i>Frontiers in Endocrinology</i> , 2021, 12, 693958.	1.5	1
233	Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. <i>Clinical Therapeutics</i> , 2021, 43, 1476-1504.	1.1	14
234	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 869.	1.7	11
235	The evolving story of incretins (<sc>GIP</sc> and <sc>GLP</sc>-1) in metabolic and cardiovascular disease: A pathophysiological update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 5-29.	2.2	139
236	MECHANISMS IN ENDOCRINOLOGY: The gut-brain axis: regulating energy balance independent of food intake. <i>European Journal of Endocrinology</i> , 2021, 185, R75-R91.	1.9	13
237	Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. <i>British Journal of Pharmacology</i> , 2022, 179, 542-556.	2.7	19
238	Gastrointestinal peptides in eating-related disorders. <i>Physiology and Behavior</i> , 2021, 238, 113456.	1.0	9
239	Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 457-474.	1.2	1
240	The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 148-153.	2.2	48
241	Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021, 30, 233-247.	1.5	3
242	Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumb: What do They Mean for Clinical Practice?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021, 30, 196-208.	1.5	27

#	ARTICLE	IF	CITATIONS
244	Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes. Journal of Nuclear Medicine, 2021, , jnumed.121.262506.	2.8	2
245	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research, 2021, 171, 105782.	3.1	72
246	Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. Pharmaceuticals, 2021, 14, 991.	1.7	28
247	Les nouvelles th�rapeutiques du diab�te. La Presse M�dicale Formation, 2021, 2, 574-574.	0.1	0
248	Application in medicine: obesity and satiety control. , 2021, , 629-664.		0
249	Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes, 2021, 12, 84-97.	1.3	15
250	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Current Obesity Reports, 2021, 10, 14-30.	3.5	136
251	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
252	The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 333-343.	1.1	9
253	Repurposing GLP1 agonists for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 91-112.	0.9	7
255	Obesity and Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, S44-S51.	0.6	5
257	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020, 5, .	2.3	177
258	Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. Journal of Clinical Investigation, 2019, 129, 3786-3791.	3.9	62
259	CNS-targeting pharmacological interventions for the metabolic syndrome. Journal of Clinical Investigation, 2019, 129, 4058-4071.	3.9	24
260	Antiobesogenic effects of central GIPR antagonism. Journal of Clinical Investigation, 2019, 129, 3532-3535.	3.9	4
261	Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions. Clinical Medicine Insights: Endocrinology and Diabetes, 2019, 12, 117955141988887.	1.0	12
262	�-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance. Journal of Endocrinology, 2020, 245, 219-230.	1.2	4
263	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. Journal of Endocrinology, 2020, 246, R65-R74.	1.2	18

#	ARTICLE	IF	CITATIONS
264	Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 749607.	1.8	12
265	Rodent diet aids and the fallacy of caloric restriction. <i>Mechanisms of Ageing and Development</i> , 2021, 200, 111584.	2.2	6
266	Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 363-378.	1.8	49
267	The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3503.	1.7	4
268	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 1811-1824.	6.3	257
269	A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 239-246.	2.2	29
270	Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2022, 43, 507-557.	8.9	39
271	Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110490.	0.5	0
272	One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1598-1612.	1.1	4
273	Impressions from EASD 2018. <i>British Journal of Diabetes</i> , 2018, 18, 180-182.	0.1	0
275	The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. <i>Diabetes Mellitus</i> , 2019, 22, 461-466.	0.5	1
276	Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture. <i>Diabetes</i> , 2021, 70, 2468-2475.	0.3	14
277	The incretin/glucagon system as a target for pharmacotherapy of obesity. <i>Obesity Reviews</i> , 2022, 23, .	3.1	26
278	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
279	Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. <i>Nutrients</i> , 2020, 12, 476.	1.7	12
280	Peptides in the regulation of glucagon secretion. <i>Peptides</i> , 2022, 148, 170683.	1.2	16
282	Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity. <i>Gastroenterology Pancreatology and Hepatobiliary Disorders</i> , 2021, 5, 01-04.	0.0	0
283	Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. <i>Molecular Metabolism</i> , 2022, 55, 101407.	3.0	24



#	ARTICLE	IF	CITATIONS
284	Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus. , 2022, 234, 108044.		13
285	Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obesity Facts, 2022, 15, 83-89.	1.6	18
286	Doubles-agonistes, tri-agonistes et multi-agonistes incrÃ©tines/glucagon. Medecine Des Maladies Metaboliques, 2021, 15, 744-744.	0.1	0
287	Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery, 2022, 21, 201-223.	21.5	357
288	The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology, 2021, 20, 225.	2.7	34
289	Pharmacology of NASH. , 2021, , .		0
290	Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 788-805.	2.2	17
291	The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism, 2022, 24, 15-27.	2.2	24
292	GLP-1/GIP/glucagon receptor triagonism gets its try in humans. Cell Metabolism, 2022, 34, 3-4.	7.2	5
293	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	3.1	13
294	Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function. Handbook of Experimental Pharmacology, 2021, , 439-465.	0.9	1
295	Drugs for Treating Obesity. Handbook of Experimental Pharmacology, 2021, , 387-414.	0.9	12
296	Efficient Estimation of the Efficacy and Safety Endpoints for Clinical Trials with Preplanned Dose Titrations. Statistics in Biopharmaceutical Research, 2023, 15, 214-224.	0.6	0
297	Sudden Cardiac Death in Diabetes and Obesity: Mechanisms and Therapeutic Strategies. Canadian Journal of Cardiology, 2022, 38, 418-426.	0.8	18
298	Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation. Molecules, 2022, 27, 830.	1.7	9
299	Non-alcoholic fatty liver disease and type-2 diabetes: An update. Journal of Diabetes Investigation, 2022, 13, 930-940.	1.1	25
300	Melanocortin-4 receptor complexity in energy homeostasis, obesity and drug development strategies. Diabetes, Obesity and Metabolism, 2022, 24, 583-598.	2.2	8
302	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). Canadian Liver Journal, 2022, 5, 61-90.	0.3	7

#	ARTICLE	IF	CITATIONS
303	Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 534.	3.8	216
304	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 281-295.	1.1	35
305	Growth differentiation factor 15 (<sc>GDF15</sc>) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1010-1020.	2.2	14
306	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2022, 166, 144-145.	0.7	3
307	Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. <i>Indian Journal of Endocrinology and Metabolism</i> , 2021, 25, 475.	0.2	30
308	Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. <i>Nature Communications</i> , 2022, 13, 1057.	5.8	46
309	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. <i>Nature Medicine</i> , 2022, 28, 591-598.	15.2	139
310	Therapeutic peptides: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 48.	7.1	454
311	The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3685-3705.	2.9	1
312	Gastrointestinal Incretinsâ€”Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Diseaseâ€”State of the Art. <i>Biology</i> , 2022, 11, 288.	1.3	9
313	Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2022, 386, e17.	13.9	10
314	Turning the clock forward: New pharmacological and not pharmacological targets for the treatment of obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	3
315	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 359-375.	0.9	22
316	Structural determinants of dual incretin receptor agonism by tirzepatide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2116506119.	3.3	31
317	The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 28-36.	1.5	15
318	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 838410.	1.5	42
319	GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 136-149.	0.9	12
321	Effects of Dietary Chromium Picolinate on Gut Microbiota, Gastrointestinal Peptides, Glucose Homeostasis, and Performance of Heat-Stressed Broilers. <i>Animals</i> , 2022, 12, 844.	1.0	5

#	ARTICLE	IF	CITATIONS
322	Comparing effects of obesity treatment with very low energy diet and bariatric surgery after 2 years: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e053242.	0.8	3
323	New Phenol Esters for Efficient pH-Controlled Amine Acylation of Peptides, Proteins, and Sepharose Beads in Aqueous Media. <i>Bioconjugate Chemistry</i> , 2022, 33, 172-179.	1.8	7
324	GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1156-1166.	2.8	11
326	Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, $\hat{\alpha}$ -Amylase Inhibitor, and Antidiabetic Agent. <i>Biomedicines</i> , 2022, 10, 24.	1.4	20
327	Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment. <i>Life</i> , 2022, 12, 29.	1.1	12
328	The Enteroendocrine System in Obesity. <i>Handbook of Experimental Pharmacology</i> , 2022, , 109-129.	0.9	6
329	Targeting the Enteroendocrine System for Treatment of Obesity. <i>Handbook of Experimental Pharmacology</i> , 2022, , 1.	0.9	0
330	A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus. <i>Appetite</i> , 2022, 174, 106022.	1.8	11
331	Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists. <i>ACS Chemical Biology</i> , 2022, 17, 1249-1258.	1.6	2
332	Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 407-417.	5.5	30
333	Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. <i>Patient</i> , 2022, 15, 367-377.	1.1	7
334	Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment. <i>Pharmacological Research</i> , 2022, 180, 106237.	3.1	3
335	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. <i>Cardiovascular Diabetology</i> , 2022, 21, 74.	2.7	82
336	Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278.	1.8	66
337	Multiagonists of the $\hat{\alpha}$ -incretin axis as a promising tool for managing cardiometabolic risk in visceral obesity. <i>Russian Journal of Cardiology</i> , 2022, 27, 4755.	0.4	0
338	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
340	Activation of GIPR Exerts Analgesic and Anxiolytic-Like Effects in the Anterior Cingulate Cortex of Mice. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	4
341	Brown Adipose Tissue "A Translational Perspective. <i>Endocrine Reviews</i> , 2023, 44, 143-192.	8.9	49

#	ARTICLE	IF	CITATIONS
342	Glucose-Dependent Insulinotropic Polypeptideâ€”A Postprandial Hormone with Unharnessed Metabolic Potential. <i>Annual Review of Nutrition</i> , 2022, 42, 21-44.	4.3	9
343	Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1547-1559.	2.0	12
344	GLP-1 analogues in clinical management of obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100360.	0.6	3
345	Multiagonists of the â€œincretin axisâ€•as a promising tool for managing cardiometabolic risk in visceral obesity. <i>Russian Journal of Cardiology</i> , 2022, 27, 4755.	0.4	1
346	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 171-179.	0.8	4
347	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. <i>Seminars in Liver Disease</i> , 2022, 42, 379-400.	1.8	17
348	Glucoseâ€dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat dietâ€fed mice. <i>British Journal of Pharmacology</i> , 2022, 179, 4486-4499.	2.7	7
350	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. , 2022, 18, 10.		12
353	Targeting fibrosis: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
354	Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. <i>Atherosclerosis</i> , 2022, 355, 30-44.	0.4	7
355	Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. <i>Molecules</i> , 2022, 27, 4315.	1.7	56
356	Tirzepatide: First Approval. <i>Drugs</i> , 2022, 82, 1213-1220.	4.9	41
357	Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. <i>Molecular Metabolism</i> , 2022, 63, 101533.	3.0	43
358	Pharmacologic treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 408-416.	0.1	0
359	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. <i>Endocrine Reviews</i> , 2023, 44, 14-32.	8.9	32
360	Next Step in Incretin-Based Therapy: From Single to Dual Agonism. <i>European Medical Journal Diabetes</i> , 0, , .	4.0	1
361	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-17.	2.2	36
362	Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans. <i>Cardiovascular Research</i> , 2023, 119, 905-918.	1.8	6

#	ARTICLE	IF	CITATIONS
363	Circadian rhythms and pancreas physiology: A review. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
364	Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes. <i>Nutrition and Diabetes</i> , 2022, 12, .	1.5	61
365	LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. <i>Cell Metabolism</i> , 2022, 34, 1234-1247.e9.	7.2	77
367	Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2022, 10, 634-644.	5.5	48
368	GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3261-3274.	1.8	5
369	Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage. <i>Current Research in Neurobiology</i> , 2022, 3, 100055.	1.1	1
370	Chapter 9. <i>In Vivo</i> Imaging of the Pancreas and Gut Hormone Receptors. <i>RSC Nanoscience and Nanotechnology</i> , 2022, , 262-291.	0.2	0
371	Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	10
372	Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. <i>Nutrients</i> , 2022, 14, 3775.	1.7	2
373	Tirzepatide. <i>Hospital Pharmacy</i> , 2023, 58, 227-243.	0.4	3
374	Differential effects of glucoseâ€dependent insulinotropic polypeptide receptor/glucagonâ€like peptideâ€1 receptor heteromerization on cell signaling when expressed in <sc>HEK</sc>â€293 cells. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	4
375	The neuroprotective effects of glucagon-like peptide 1 in Alzheimerâ€™s and Parkinsonâ€™s disease: An in-depth review. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	39
376	Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). <i>Medical Science Monitor</i> , 0, 28, .	0.5	7
377	Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2022, 10, 774-785.	5.5	71
378	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	79
379	Change in pharmacodynamic variables following onceâ€weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (<sc>SURPASS</sc> Jâ€mono substudy). <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 398-406.	2.2	13
380	Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. <i>Biomedicines</i> , 2022, 10, 2586.	1.4	6
381	Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12305.	1.8	19

#	ARTICLE	IF	CITATIONS
382	LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. <i>Lancet</i> , The, 2022, 400, 1869-1881.	6.3	78
383	Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
384	The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12572.	1.8	20
385	Harnessing the Incretin System with Multi-Agonists. <i>European Medical Journal Innovations</i> , 0, , .	2.0	1
386	Semaglutide for the treatment of overweight and obesity: A review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 18-35.	2.2	26
387	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	21
388	Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102640.	1.8	16
389	Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2023, 57, 822-836.	0.9	5
391	Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma. <i>Clinical and Experimental Allergy</i> , 2023, 53, 216-221.	1.4	1
392	Emerging pharmacological treatment options for MAFLD. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211424.	1.4	4
393	Obesity pharmacotherapy: incretin action in the central nervous system. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 50-63.	4.0	10
394	Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
395	Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers. <i>Clinical Diabetes</i> , 0, , .	1.2	4
396	New therapies for obesity. <i>Cardiovascular Research</i> , 2024, 119, 2825-2842.	1.8	16
397	Tirzepatide: A Systematic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14631.	1.8	12
398	Tirzepatide (Mounjaro): A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus. <i>American Journal of Therapeutics</i> , 0, Publish Ahead of Print, .	0.5	3
399	Tirzepatide for the treatment of obesity: Rationale and design of the <sc>SURMOUNT</sc> clinical development program. <i>Obesity</i> , 2023, 31, 96-110.	1.5	22
400	Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity. <i>Applied Biochemistry and Microbiology</i> , 2022, 58, 854-863.	0.3	1

#	ARTICLE	IF	CITATIONS
401	Obesity and diabetes: the final frontier. Expert Review of Endocrinology and Metabolism, 2023, 18, 81-94.	1.2	4
402	GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2023, 24, 1703.	1.8	31
403	Metabolic Messengers: glucagon. Nature Metabolism, 2023, 5, 186-192.	5.1	9
404	Does glucose lowering restore GIP effects on insulin secretion?. Nutrition, Metabolism and Cardiovascular Diseases, 2023, , .	1.1	2
405	Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Annales D'Endocrinologie, 2023, 84, 316-321.	0.6	15
406	The effectiveness and value of tirzepatide for type 2 diabetes mellitus. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 680-684.	0.5	1
407	Adverse Events Related to Tirzepatide. Journal of the Endocrine Society, 2023, 7, .	0.1	13
408	Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice. British Journal of Pharmacology, 2023, 180, 1674-1689.	2.7	3
409	Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Frontiers in Endocrinology, 0, 14, .	1.5	7
410	Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review. Journal of Education, Health and Sport, 2023, 18, 23-33.	0.0	0
411	Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice. Atherosclerosis, 2023, 372, 19-31.	0.4	2
413	New Drug: Tirzepatide (Mounjaro <sup>®</sup> ). , 2023, 38, 50-62.		2
414	Hormonal Gut-Brain Signaling for the Treatment of Obesity. International Journal of Molecular Sciences, 2023, 24, 3384.	1.8	8
415	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity and Metabolic Syndrome, 2023, 32, 25-45.	1.5	14
416	Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system. Biomedicine and Pharmacotherapy, 2023, 160, 114383.	2.5	2
417	An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Review of Endocrinology and Metabolism, 2023, 18, 111-130.	1.2	3
418	Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. Expert Opinion on Pharmacotherapy, 2023, 24, 407-418.	0.9	2
419	Metabolically healthy obesity: Misleading phrase or healthy phenotype?. European Journal of Internal Medicine, 2023, 111, 5-20.	1.0	14

#	ARTICLE	IF	CITATIONS
420	Pharmacological inhibitors of Î²-cell dysfunction and death as therapeutics for diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
421	Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. <i>Nature Reviews Endocrinology</i> , 2023, 19, 321-335.	4.3	28
422	Diabesity and the Kidney. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 168-207.	0.1	0
423	The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. <i>Patient Preference and Adherence</i> , 0, Volume 17, 793-805.	0.8	1
424	A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
425	The expanding incretin universe: from basic biology to clinical translation. <i>Diabetologia</i> , 2023, 66, 1765-1779.	2.9	26
427	Tirzepatide decreases systolic and diastolic blood pressure. <i>European Journal of Internal Medicine</i> , 2023, 114, 135-137.	1.0	3
428	Design, synthesis, and biological evaluation of a potential long-acting glucagon-like peptide-1 (GLP-1) analog. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 85, 117291.	1.4	0
429	Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1). <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	8
440	Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. <i>International Journal of Obesity</i> , 2023, 47, 677-685.	1.6	10
457	Gut hormone co-agonists for the treatment of obesity: from bench to bedside. <i>Nature Metabolism</i> , 2023, 5, 933-944.	5.1	15
465	Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. <i>International Journal of Obesity</i> , 2023, 47, 883-892.	1.6	8
479	Potential Pharmaceutical and Non-pharmaceutical Approaches to Obesity and Diabetes: Focus on Inflammation. <i>Contemporary Endocrinology</i> , 2023, , 207-227.	0.3	0
480	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
489	A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres. <i>Journal of Materials Chemistry B</i> , 2023, 11, 11184-11197.	2.9	0
501	Polygonists in Type 2 Diabetes Management. <i>Current Diabetes Reports</i> , 0, , .	1.7	0
510	The cardiometabolic syndrome and vascular disease: pivotal role of insulin. , 2023, , 261-284.		0
512	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0



#	ARTICLE	IF	CITATIONS
---	---------	----	-----------